Table 1.

Demographical and clinical status of the participants.

	SF (n = 52)	NSF (n = 22)	x 2 /Z/t -value	P- value
Sex (Male/female)	33/19	11/11	1.162a	0.281
Age, year	14.5 ± 11.50	16.50 ± 12.00	−0.681b	0.496
Age at onset, year	13.5 ± 12.25	15.50 ± 13.38	−0.361b	0.718
Follow-up time, months	32.58 ± 9.83	36.18 ± 8.91	−1.481c	0.143
Seizure frequency before OXC, times/month	0.65 ± 0.70	15.50 ± 13.37	−1.983b	0.045*
Seizure circadian rhythm (day/night/both)	19/16/17	8/7/7	0.009a	0.995
Comorbidity (Y/N)	27/25	16/6	2.749a	0.097
Inducement (Y/N)	29/23	17/5	3.039a	0.081
History of perinatal injury (Y/N)	12/40	12/10	6.986a	0.008*
Physical development (N/AN)	9/43	3/19	4.469a	0.035*
Family history (Y/N)	2/50	2/20	0.832a	0.362
MRI(P/N)	17/35	13/9	4.469a	0.035 *
TLE(Y/N)	16/36	8/14	0.221a	0.638
History of CNS infection (Y/N)	7/45	2/20	0.261a	0.599
History of head injury (Y/N)	5/47	2/20	0.005a	0.944

SF, seizure-free; NSF, not seizure-free; OXC, oxcarbazepine; Y/N, yes/no; N/AN, normal/abnormal; P/N, positive/negative; MRI, magnetic resonance imaging; TLE, temporal lobe epilepsy; CNS, central nervous system.

^aFor qualitative data, Chi-square tests were used.

^bFor quantitative data, after Shapiro-Wilk normality test, the Mann-Whitney U-test was applied for data with abnormal distributions, data that did not conform to normal distributions were presented as the median ± interquartile range.

^cData with a normal distribution were compared by the independent sample t-tests, mean ± standard deviation was used to describe. p < 0.05 is considered as statistically significant.

^*Defined as features that have statistically significant between SF group and NSF group.

Bold values are statistically significant.